|
US5521184A
(en)
|
1992-04-03 |
1996-05-28 |
Ciba-Geigy Corporation |
Pyrimidine derivatives and processes for the preparation thereof
|
|
ES2342240T3
(es)
|
1998-08-11 |
2010-07-02 |
Novartis Ag |
Derivados de isoquinolina con actividad que inhibe la angiogenia.
|
|
US6133031A
(en)
|
1999-08-19 |
2000-10-17 |
Isis Pharmaceuticals Inc. |
Antisense inhibition of focal adhesion kinase expression
|
|
GB9905075D0
(en)
|
1999-03-06 |
1999-04-28 |
Zeneca Ltd |
Chemical compounds
|
|
GB0004890D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
|
EP1294358B1
(en)
|
2000-06-28 |
2004-08-18 |
Smithkline Beecham Plc |
Wet milling process
|
|
CN100391958C
(zh)
|
2001-09-19 |
2008-06-04 |
安万特医药股份有限公司 |
化合物
|
|
PT1441737E
(pt)
|
2001-10-30 |
2006-12-29 |
Dana Farber Cancer Inst Inc |
Derivados de estrutura como inibidores da actividade do receptor de tirosina cinase flt3
|
|
EP1456652A4
(en)
|
2001-11-13 |
2005-11-02 |
Dana Farber Cancer Inst Inc |
IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
|
|
NZ534069A
(en)
|
2002-01-22 |
2007-03-30 |
Warner Lambert Co |
2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
|
|
PE20040522A1
(es)
|
2002-05-29 |
2004-09-28 |
Novartis Ag |
Derivados de diarilurea dependientes de la cinasa de proteina
|
|
GB0215676D0
(en)
|
2002-07-05 |
2002-08-14 |
Novartis Ag |
Organic compounds
|
|
AR042052A1
(es)
|
2002-11-15 |
2005-06-08 |
Vertex Pharma |
Diaminotriazoles utiles como inhibidores de proteinquinasas
|
|
UA80767C2
(en)
|
2002-12-20 |
2007-10-25 |
Pfizer Prod Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
|
ES2367430T3
(es)
|
2002-12-23 |
2011-11-03 |
Wyeth Llc |
Anticuerpos contra pd-1 y sus usos.
|
|
GB0305929D0
(en)
|
2003-03-14 |
2003-04-23 |
Novartis Ag |
Organic compounds
|
|
EP1667694B1
(en)
|
2003-09-05 |
2010-04-28 |
Anadys Pharmaceuticals, Inc. |
Tlr7 ligands for the treatment of hepatitis c
|
|
PE20050952A1
(es)
|
2003-09-24 |
2005-12-19 |
Novartis Ag |
Derivados de isoquinolina como inhibidores de b-raf
|
|
RU2384571C2
(ru)
|
2004-04-28 |
2010-03-20 |
Такеда Фармасьютикал Компани Лимитед |
Конденсированное хинолиновое производное и его применение
|
|
WO2006038923A2
(en)
|
2004-06-18 |
2006-04-13 |
3M Innovative Properties Company |
Aryl substituted imidazonaphthyridines
|
|
CA2578975A1
(en)
|
2004-09-02 |
2006-03-16 |
3M Innovative Properties Company |
2-amino 1h imidazo ring systems and methods
|
|
RU2007123675A
(ru)
|
2004-11-24 |
2008-12-27 |
Новартис АГ (CH) |
Комбинации ингибиторов jak
|
|
JP2008532933A
(ja)
|
2005-02-11 |
2008-08-21 |
コーリー ファーマシューティカル グループ，インコーポレイテッド |
置換イミダゾキノリン類および置換イミダゾナフチリジン類
|
|
US8158794B2
(en)
|
2005-02-23 |
2012-04-17 |
3M Innovative Properties Company |
Hydroxyalkyl substituted imidazoquinoline compounds and methods
|
|
EP1850849A2
(en)
|
2005-02-23 |
2007-11-07 |
Coley Pharmaceutical Group, Inc. |
Method of preferentially inducing the biosynthesis of interferon
|
|
EP3530736A3
(en)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
|
KR101704734B1
(ko)
|
2005-07-01 |
2017-02-09 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
GB0522715D0
(en)
|
2005-11-08 |
2005-12-14 |
Helperby Therapeutics Ltd |
New use
|
|
GB0709513D0
(en)
|
2007-05-17 |
2007-06-27 |
Helperby Therapeutics Ltd |
Topical formulations
|
|
EP1972629A1
(en)
|
2007-03-23 |
2008-09-24 |
Mutabilis SA |
New imidazolo-heteroaryl derivatives with antibacterial properties
|
|
PT2170959E
(pt)
|
2007-06-18 |
2014-01-07 |
Merck Sharp & Dohme |
Anticorpos para o receptor humano de morte programada pd-1
|
|
AU2008343932B2
(en)
|
2007-12-19 |
2013-08-15 |
Amgen Inc. |
Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
US8436005B2
(en)
|
2008-04-03 |
2013-05-07 |
Abbott Laboratories |
Macrocyclic pyrimidine derivatives
|
|
JP2012502067A
(ja)
|
2008-09-10 |
2012-01-26 |
カリプシス・インコーポレーテッド |
疾患の治療のためのヒスタミン受容体の複素環阻害剤
|
|
WO2010036959A2
(en)
|
2008-09-26 |
2010-04-01 |
Dana-Farber Cancer Institute |
Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
|
|
US20110263588A1
(en)
|
2008-10-27 |
2011-10-27 |
Glaxo Group Limited |
Tricyclic compounds as glutamate receptor modulators
|
|
MX356367B
(es)
|
2008-12-09 |
2018-05-25 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
|
|
PA8852901A1
(es)
|
2008-12-22 |
2010-07-27 |
Lilly Co Eli |
Inhibidores de proteina cinasa
|
|
WO2010089411A2
(en)
|
2009-02-09 |
2010-08-12 |
Universite De La Mediterranee |
Pd-1 antibodies and pd-l1 antibodies and uses thereof
|
|
US20100298302A1
(en)
|
2009-05-20 |
2010-11-25 |
Fabrice Pierre |
Novel protein kinase modulators
|
|
US8637670B2
(en)
|
2009-06-30 |
2014-01-28 |
Piramal Enterprises Limited |
Imidazo [4,5-C]quinoline derivatives and their use in the treatment of tumors and/or inflammation
|
|
KR20120063515A
(ko)
|
2009-09-09 |
2012-06-15 |
아빌라 테라퓨틱스, 인크. |
Ｐｉ３ 키나제 억제제 및 이들의 용도
|
|
GB0919423D0
(en)
|
2009-11-05 |
2009-12-23 |
Glaxosmithkline Llc |
Novel compounds
|
|
EP2504028A4
(en)
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
|
|
US20130022629A1
(en)
|
2010-01-04 |
2013-01-24 |
Sharpe Arlene H |
Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
|
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
|
JP5863058B2
(ja)
|
2010-05-17 |
2016-02-16 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
１Ｈ−イミダゾ［４，５−ｃ］キノリン
|
|
US9163087B2
(en)
|
2010-06-18 |
2015-10-20 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
US9062046B2
(en)
|
2010-07-16 |
2015-06-23 |
Piramal Enterprises Limited |
Substituted imidazoquinoline derivatives as kinase inhibitors
|
|
WO2012011642A1
(ko)
|
2010-07-23 |
2012-01-26 |
고려대학교 산학협력단 |
염료감응 태양전지용 준고체 고분자 전해질, 그에 포함되는 정공수송물질, 및 그 전해질을 포함하는 염료감응 태양전지
|
|
CN102399218A
(zh)
|
2010-09-16 |
2012-04-04 |
和记黄埔医药（上海）有限公司 |
一类并合三杂环及其作为pi3k抑制剂的用途
|
|
KR102186969B1
(ko)
|
2010-10-25 |
2020-12-04 |
쥐원 쎄라퓨틱스, 인크. |
Cdk 억제제
|
|
KR101606250B1
(ko)
|
2011-03-23 |
2016-03-24 |
암젠 인크 |
Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제
|
|
WO2012154731A1
(en)
|
2011-05-08 |
2012-11-15 |
Vanderbilt University |
Substituted 1h-pyrrolo[3,2-c]quinolin-4(5h)-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
|
|
WO2013033268A2
(en)
|
2011-08-29 |
2013-03-07 |
Coferon, Inc. |
Bivalent bromodomain ligands, and methods of using same
|
|
US9169246B2
(en)
|
2011-09-26 |
2015-10-27 |
Sanofi |
Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof
|
|
CN103012397B
(zh)
|
2011-09-26 |
2017-03-01 |
赛诺菲 |
吡唑并喹啉酮衍生物、其制备方法及其治疗用途
|
|
SI2573073T1
(sl)
|
2011-09-26 |
2015-02-27 |
Sanofi |
Pirazolokinolinonski derivati, njihova priprava in njihova terapevtska uporaba
|
|
CA2850932A1
(en)
|
2011-10-04 |
2013-04-11 |
Janus Biotherapeutics, Inc. |
Novel imidazole quinoline-based immune system modulators
|
|
CN103930423B
(zh)
|
2011-10-07 |
2015-09-16 |
卫材Rd管理有限公司 |
吡唑并喹啉衍生物
|
|
EP2968285A4
(en)
|
2013-03-13 |
2016-12-21 |
Flatley Discovery Lab |
COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
|
|
JP5666755B1
(ja)
|
2013-04-05 |
2015-02-12 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ピラゾロキノリン誘導体の塩およびその結晶
|
|
ES2654094T3
(es)
|
2013-04-05 |
2018-02-12 |
Eisai R&D Management Co., Ltd. |
Compuestos piridinilpirazoloquinolina
|
|
US9227969B2
(en)
*
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
|
WO2015073804A2
(en)
|
2013-11-15 |
2015-05-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Method of blocking transmission of malarial parasite
|
|
WO2016141296A1
(en)
|
2015-03-04 |
2016-09-09 |
Dana-Farber Caner Institute, Inc. |
Tricyclic kinase inhibitors of melk and methods of use
|
|
WO2016161361A1
(en)
|
2015-04-03 |
2016-10-06 |
Nantbioscience, Inc. |
Compositions and methods of targeting mutant k-ras
|
|
ES2856880T3
(es)
*
|
2015-04-15 |
2021-09-28 |
Araxes Pharma Llc |
Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos
|
|
WO2016199943A1
(en)
|
2015-06-11 |
2016-12-15 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compounds
|
|
PE20231958A1
(es)
|
2015-07-30 |
2023-12-06 |
Macrogenics Inc |
Moleculas de union a pd-1 y metodos de uso de las mismas
|
|
RU2722149C1
(ru)
|
2015-09-14 |
2020-05-27 |
Пфайзер Инк. |
Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
|
|
US10730867B2
(en)
|
2015-09-28 |
2020-08-04 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
US20170107216A1
(en)
|
2015-10-19 |
2017-04-20 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
KR102932353B1
(ko)
*
|
2015-11-16 |
2026-02-27 |
아락세스 파마 엘엘씨 |
치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
|
|
MD3377488T2
(ro)
|
2015-11-19 |
2023-02-28 |
Incyte Corp |
Compuși heterociclici ca imunomodulatori
|
|
CN106188138B
(zh)
|
2015-12-02 |
2018-07-24 |
深圳市塔吉瑞生物医药有限公司 |
一种二氨基嘧啶化合物及包含该化合物的组合物
|
|
ES2916874T3
(es)
|
2015-12-17 |
2022-07-06 |
Incyte Corp |
Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
|
|
CA3009474A1
(en)
|
2015-12-22 |
2017-06-29 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
US10730871B2
(en)
|
2016-01-28 |
2020-08-04 |
Regents Of The University Of Minnesota |
Immunomodulators and immunomodulator conjugates
|
|
KR102606277B1
(ko)
|
2016-04-06 |
2023-11-27 |
삼성디스플레이 주식회사 |
유기 발광 소자
|
|
ES2906460T3
(es)
|
2016-05-06 |
2022-04-18 |
Incyte Corp |
Compuestos heterocíclicos como inmunomoduladores
|
|
ES2863873T3
(es)
|
2016-05-18 |
2021-10-11 |
Mirati Therapeutics Inc |
Inhibidores de KRAS G12C
|
|
EP3464279B1
(en)
|
2016-05-26 |
2021-11-24 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
SG11201811414TA
(en)
|
2016-06-20 |
2019-01-30 |
Incyte Corp |
Heterocyclic compounds as immunomodulators
|
|
MA45669A
(fr)
|
2016-07-14 |
2019-05-22 |
Incyte Corp |
Composés hétérocycliques utilisés comme immunomodulateurs
|
|
US20180057486A1
(en)
|
2016-08-29 |
2018-03-01 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
WO2018119263A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Heterocyclic compounds derivatives as pd-l1 internalization inducers
|
|
CR20190338A
(es)
|
2016-12-22 |
2019-09-09 |
Amgen Inc |
Inhibidores de kras g12c y métodos para su uso
|
|
EP4223369A1
(en)
|
2016-12-22 |
2023-08-09 |
Incyte Corporation |
Immunomodulator compounds and methods of use
|
|
WO2018119286A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Bicyclic heteroaromatic compounds as immunomodulators
|
|
WO2018119236A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Triazolo[1,5-a]pyridine derivatives as immunomodulators
|
|
US10308644B2
(en)
|
2016-12-22 |
2019-06-04 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
WO2018119221A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Pyridine derivatives as immunomodulators
|
|
CN108794467A
(zh)
|
2017-04-27 |
2018-11-13 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
|
UA127968C2
(uk)
|
2017-05-22 |
2024-02-28 |
Емджен Інк. |
Інгібітори g12c kras і способи їх застосування
|
|
CA3082579A1
(en)
|
2017-11-15 |
2019-05-23 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
US10647715B2
(en)
|
2017-11-15 |
2020-05-12 |
Mirati Therapeutics, Inc. |
KRas G12C inhibitors
|
|
CN108003153B
(zh)
|
2017-11-24 |
2021-04-30 |
中国医学科学院肿瘤医院 |
含氮五元杂环并喹啉类化合物及其盐、制法、药物组合物和用途
|
|
US10597405B2
(en)
|
2017-12-08 |
2020-03-24 |
Astrazeneca Ab |
Chemical compounds
|
|
SMT202300065T1
(it)
|
2018-03-30 |
2023-05-12 |
Incyte Corp |
Composti eterociclici come immunomodulatori
|
|
WO2019201283A1
(en)
|
2018-04-20 |
2019-10-24 |
Xrad Therapeutics, Inc. |
Dual atm and dna-pk inhibitors for use in anti-tumor therapy
|
|
WO2019209896A1
(en)
|
2018-04-25 |
2019-10-31 |
Innate Tumor Immunity, Inc. |
Nlrp3 modulators
|
|
MX2020010836A
(es)
|
2018-05-04 |
2021-01-08 |
Amgen Inc |
Inhibidores de kras g12c y métodos para su uso.
|
|
CN112752756B
(zh)
|
2018-05-11 |
2024-06-25 |
因赛特公司 |
作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物
|
|
CN113038989A
(zh)
|
2018-08-16 |
2021-06-25 |
先天肿瘤免疫公司 |
咪唑并[4,5-c]喹啉衍生的nlrp3调节剂
|
|
JP7433291B2
(ja)
|
2018-08-16 |
2024-02-19 |
イネイト・テューマー・イミュニティ・インコーポレイテッド |
イミダゾ［４，５－ｃ］キノリン誘導体のＮＬＲＰ３モジュレーター
|
|
WO2020055755A1
(en)
|
2018-09-10 |
2020-03-19 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
WO2021142252A1
(en)
*
|
2020-01-10 |
2021-07-15 |
Incyte Corporation |
Tricyclic compounds as inhibitors of kras
|
|
WO2021150613A1
(en)
|
2020-01-20 |
2021-07-29 |
Incyte Corporation |
Spiro compounds as inhibitors of kras
|
|
CN121270550A
(zh)
|
2020-04-16 |
2026-01-06 |
因赛特公司 |
稠合三环kras抑制剂
|
|
WO2021231526A1
(en)
|
2020-05-13 |
2021-11-18 |
Incyte Corporation |
Fused pyrimidine compounds as kras inhibitors
|
|
WO2022047093A1
(en)
|
2020-08-28 |
2022-03-03 |
Incyte Corporation |
Vinyl imidazole compounds as inhibitors of kras
|
|
WO2022072783A1
(en)
|
2020-10-02 |
2022-04-07 |
Incyte Corporation |
Bicyclic dione compounds as inhibitors of kras
|